INNOVATION IS THE NEED OF THE HOUR FOR INDIAN PHARMA

Dear Reader, Addressing the IDMA’s 63rd Annual Day Celebration, on 8th February 2025, the Chief Guest Hon. Minister for Commerce and Industry, Shri Piyush Goyal exhorted the Indian Pharma Industry to invest increasingly in Quality and Innovation. He complimented Dr. Habil Khorakiwala, CMD of Wockhardt, who was the Keynote Speaker on this occasion, for the intensive investments, financially and creatively into new drug innovations, especially launching of NCE’s from India in recent times. A few days earlier, Wockhardt and Khorakiwala team had launched their new investigational drug, Zaynich (WCK5222), formed with Zidebactam + Cefepime in combination, for treatment of gram-negative infections, alongwith five other investigational new drugs. Zaynich has been successful on “Compassionate Use”, for Bacteremia, Pneumonia (HABP/VABP), meningitis, complicated multidrug resistant abdominal infections in India and USA, most successfully at Medanta Hospital, Lucknow. Other molecules such as Nafithromycin was launched by Dr. Jitendra Singh, Minister of State, which was an NCE developed by Wockhardt, India’s first indigenous Macrolide antibiotic.